Cardiology, Department of Pharmacy, University of North Carolina (UNC) Hospitals, Chapel Hill, USA.
Am J Health Syst Pharm. 2011 May 15;68(10):893-8. doi: 10.2146/ajhp100321.
PURPOSE. Use of nomograms based on the "heparin correlation value" (HCV)-a value that corresponds to measured activated partial thromboplastin time (aPTT) and that removes the need to revise nomograms in response to a change in the aPTT reagent or coagulometer used-was evaluated as an alternative to traditional aPTT-based anticoagulation nomograms. SUMMARY. Data were collected on patients receiving heparin therapy for selected indications (thrombotic disorders, cardiac conditions, and acute coronary syndromes) during four-month periods before (n = 59) and after (n = 60) implementation of the HCV-based nomograms. The primary endpoints were the rate at which coagulation laboratory measurements were obtained at the appropriate time and the rate of appropriate dosage adjustment in response to reported laboratory values; secondary endpoints included the time to attainment of the first target anticoagulation value. After implementation of HCV-based nomograms, coagulation laboratory measurements were obtained at the appropriate time in (mean ± S.D.) 92.9% ± 12.8% of patients, compared with 80.1% ± 15.5% of patients who received aPTT-based monitoring (p < 0.0001). After implementation of HCV-based monitoring, the rate of correct heparin dosage adjustments was improved (mean ± S.D. 94.7% ± 7.8% versus 89.3% ± 14.0%, p = 0.01), and the time to attainment of the first target anticoagulation value was shorter (mean ± S.D. 16.4 ± 10.6 hours versus 21.5 ± 14.8 hours, p = 0.03). CONCLUSION. The HCV, which relates measured aPTT values to corresponding antifactor Xa concentrations, was substituted for aPTT in heparin nomograms and appeared to be a viable alternative to the aPTT.
目的。使用基于“肝素相关值”(HCV)的列线图——一种与测定的活化部分凝血活酶时间(aPTT)相对应的值,并且无需根据使用的 aPTT 试剂或凝血仪的变化来修正列线图——来替代传统的基于 aPTT 的抗凝列线图。 总结。在 HCV 列线图实施前(n = 59)和实施后(n = 60)的四个月期间,分别收集了接受肝素治疗的选定适应症(血栓性疾病、心脏疾病和急性冠脉综合征)患者的数据。主要终点是在适当的时间获得凝血实验室测量值的比例以及根据报告的实验室值进行适当剂量调整的比例;次要终点包括达到第一个目标抗凝值的时间。实施 HCV 列线图后,与接受 aPTT 监测的患者(80.1%±15.5%)相比,在适当时间获得凝血实验室测量值的患者比例增加到 92.9%±12.8%(p < 0.0001)。实施 HCV 监测后,肝素剂量调整正确的比例提高(94.7%±7.8%比 89.3%±14.0%,p = 0.01),达到第一个目标抗凝值的时间缩短(16.4±10.6 小时比 21.5±14.8 小时,p = 0.03)。 结论。HCV 将测定的 aPTT 值与相应的抗因子 Xa 浓度相关联,并用其替代 aPTT 用于肝素列线图,似乎是 aPTT 的可行替代方法。